Global Biosimilar Monoclonal Antibody Market Growth (Status and Outlook) 2023-2029

Global Biosimilar Monoclonal Antibody Market Growth (Status and Outlook) 2023-2029

Monoclonal antibodies (mAb) are antibodies produced by using identical immune cells that are clones of one unique parent cell. Since monoclonal antibodies are produced from clones of only one parent cell, all monoclonal antibodies produced by the parent cell are the same due to which, they are called biosimilar monoclonal antibodies.

Biosimilar Monoclonal Antibodies refer to the biologic medical product that are almost an identical copy of the original monoclonal antibodies but manufactured by a different company.

LPI (LP Information)' newest research report, the “Biosimilar Monoclonal Antibody Industry Forecast” looks at past sales and reviews total world Biosimilar Monoclonal Antibody sales in 2022, providing a comprehensive analysis by region and market sector of projected Biosimilar Monoclonal Antibody sales for 2023 through 2029. With Biosimilar Monoclonal Antibody sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Biosimilar Monoclonal Antibody industry.

This Insight Report provides a comprehensive analysis of the global Biosimilar Monoclonal Antibody landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Biosimilar Monoclonal Antibody portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Biosimilar Monoclonal Antibody market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Biosimilar Monoclonal Antibody and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Biosimilar Monoclonal Antibody.

The global Biosimilar Monoclonal Antibody market size is projected to grow from US$ 4411.1 million in 2022 to US$ 5622.5 million in 2029; it is expected to grow at a CAGR of 3.5% from 2023 to 2029.

Global Biosimilar Monoclonal Antibodies key players include Celltrion, 3SBIO, Pfizer (Hospira), Novartis (Sandoz), etc. Global top four manufacturers hold a share nearly 85%.

Europe is the largest market, with a share about 40%, followed by China, and United States, both have a share about 50 percent.

In terms of product, Infliximab is the largest segment, with a share nearly 40%. And in terms of application, the largest application is Autoimmune Disease, followed by Oncology, etc.

This report presents a comprehensive overview, market shares, and growth opportunities of Biosimilar Monoclonal Antibody market by product type, application, key players and key regions and countries.

Market Segmentation:

Segmentation by type
Limited Dilution Method
Micromanipulation
Soft Agar Plate Method
Others

Segmentation by application
Chronic & Autoimmune Diseases
Oncology
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Biocon
Accord Healthcare
AET Biotech
Amgen
Celltrion
Reddy's Laboratories
Hospira
3SBio
Allergan
Alvartis

Please note: The report will take approximately 2 business days to prepare and deliver.